Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
暂无分享,去创建一个
Peng Zhan | Xiao Ding | Ye Tian | Dongwei Kang | Jian Zhang | Vasanthanathan Poongavanam | Natarajan Arul Murugan | Dongwei Kang | Zengjun Fang | P. Zhan | Xinyong Liu | Vasanthanathan Poongavanam | N. A. Murugan | A. Loregian | Wenfang Xu | Xiao Ding | Jian Zhang | Zhuosen Sun | Bing Huang | Xinyong Liu | Ping Gao | Ye Tian | Arianna Loregian | Zengjun Fang | Chiara Bertagnin | Xiujie Kong | Haiyong Jia | Zhuosen Sun | Ruifang Jia | Ping Gao | Wenfang Xu | Xiuli Ma | Bing Huang | Xiuli Ma | Chiara Bertagnin | Ruifang Jia | Xiujie Kong | Haiyong Jia
[1] R. Webby,et al. The avian and mammalian host range of highly pathogenic avian H5N1 influenza. , 2013, Virus research.
[2] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[3] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[4] Alan J. Hay,et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.
[5] G. Palù,et al. Antiviral strategies against influenza virus: towards new therapeutic approaches , 2014, Cellular and Molecular Life Sciences.
[6] T. Sakai,et al. Low growth ability of recent influenza clinical isolates in MDCK cells is due to their low receptor binding affinities. , 2006, Microbes and infection.
[7] H. Ågren,et al. Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. , 2018, ACS chemical neuroscience.
[8] S. Genheden,et al. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.
[9] G. Boivin,et al. Influenza virus resistance to neuraminidase inhibitors. , 2013, Antiviral research.
[10] Peng Zhan,et al. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. , 2016, Journal of medicinal chemistry.
[11] James M Aramini,et al. Structures of influenza A proteins and insights into antiviral drug targets , 2010, Nature Structural &Molecular Biology.
[12] J. McKimm-Breschkin,et al. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance , 2013, Influenza and other respiratory viruses.
[13] I. Cornella-Taracido,et al. Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts. , 2017, Journal of medicinal chemistry.
[14] Bertrand R. Caré,et al. Rescue of a H3N2 Influenza Virus Containing a Deficient Neuraminidase Protein by a Hemagglutinin with a Low Receptor-Binding Affinity , 2012, PloS one.
[15] L. Goracci,et al. Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. , 2013, Journal of medicinal chemistry.
[16] C. Breneman,et al. Determining atom‐centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis , 1990 .
[17] Kousuke Saito,et al. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. , 2013, Antiviral research.
[18] C. Perry,et al. Oseltamivir , 2012, Drugs.
[19] K. Goa,et al. Zanamivir , 1999, Drugs.
[20] Yuguang Mu,et al. Plasticity of 150-Loop in Influenza Neuraminidase Explored by Hamiltonian Replica Exchange Molecular Dynamics Simulations , 2013, PloS one.
[21] G. Du,et al. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. , 2008, Bioorganic & medicinal chemistry.
[22] Giorgio Palù,et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase , 2012, Proceedings of the National Academy of Sciences.
[23] Robert V. Swift,et al. Mechanism of 150-cavity formation in influenza neuraminidase , 2011, Nature communications.
[24] A. Yang,et al. A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity. , 2011, Journal of the American Chemical Society.
[25] Peter D Gibbons,et al. Identification, Design and Biological Evaluation of Bisaryl Quinolones Targeting Plasmodium falciparum Type II NADH:Quinone Oxidoreductase (PfNDH2) , 2012, Journal of medicinal chemistry.
[26] Uko Maran,et al. Design of Multi-Binding-Site Inhibitors, Ligand Efficiency, and Consensus Screening of Avian Influenza H5N1 Wild-Type Neuraminidase and of the Oseltamivir-Resistant H274Y Variant , 2008, J. Chem. Inf. Model..
[27] David J. Stevens,et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.
[28] G. Gao,et al. Bat-derived influenza-like viruses H17N10 and H18N11 , 2014, Trends in Microbiology.
[29] Kuo-Chen Chou,et al. Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. , 2010, Biochemical and biophysical research communications.
[30] Holger Gohlke,et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.
[31] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[32] M. Kiso,et al. A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions. , 2016, Journal of medicinal chemistry.
[33] L. Goracci,et al. Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. , 2014, Journal of medicinal chemistry.
[34] H. Ågren,et al. The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. , 2016, The journal of physical chemistry letters.
[35] J. Andrew McCammon,et al. Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations , 2009, Journal of the American Chemical Society.
[36] Andrew G. Watts,et al. Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives. , 2018, Journal of medicinal chemistry.
[37] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[38] Jianhua He,et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site , 2010, Nature Structural &Molecular Biology.
[39] M. Eichelberger,et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] Virapong Prachayasittikul,et al. Exploring the chemical space of influenza neuraminidase inhibitors , 2016, PeerJ.
[41] Peng Zhan,et al. Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. , 2017, Journal of medicinal chemistry.
[42] David Baltimore,et al. Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.
[43] George F. Gao,et al. Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition , 2011, PLoS pathogens.
[44] Vasanthanathan Poongavanam,et al. Integrative approaches in HIV‐1 non‐nucleoside reverse transcriptase inhibitor design , 2018 .
[45] P. Kerry,et al. Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor. , 2014, Angewandte Chemie.
[46] Gabriele Neumann,et al. Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.
[47] M. Schmidtke,et al. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors , 2006, Medical Microbiology and Immunology.
[48] C. D. de Haan,et al. Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors. , 2014, Journal of medicinal chemistry.
[49] P. Kollman,et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.
[50] Ivan Merelli,et al. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase. , 2009, Biochemical and biophysical research communications.
[51] L. Goracci,et al. A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. , 2015, Journal of medicinal chemistry.
[52] Peng Zhan,et al. Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. , 2018, Journal of medicinal chemistry.
[53] Xinyong Liu,et al. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. , 2014, Journal of medicinal chemistry.
[54] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[55] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[56] An-Suei Yang,et al. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. , 2007, Journal of the American Chemical Society.
[57] G. Ayora-Talavera,et al. Hemagglutinin variants of influenza A(H1N1)pdm09 virus with reduced affinity for sialic acid receptors , 2014, Archives of Virology.
[58] A J Elliott,et al. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. , 2001, Journal of medicinal chemistry.